HealthDay News — The FDA has approved Surfaxin (lucinactant) to prevent respiratory distress syndrome (RDS) in premature infants. Premature infants born before 37 weeks’ gestation often cannot produce ...

The innovation—a handheld dry powder inhaler for newborns in respiratory distress—recently cleared a proof-of-concept milestone, with results published in a peer-reviewed journal. Now, inventors ...

Please provide your email address to receive an email when new articles are posted on . Minimally invasive surfactant therapy did not lower mortality among preterm infants with respiratory distress ...

Objective: The aim of the study was to measure pulmonary mechanics in infants with respiratory distress syndrome before extubation and to correlate pulmonary function values with successful extubation ...

Infants born full term to mothers who were infected with COVID-19 during pregnancy had three times the risk of having respiratory distress compared with unexposed infants, even though they themselves ...

The results show COVID shots in pregnancy can offer protection, researchers say. Unvaccinated pregnant people who contracted COVID-19 were more likely to have babies who suffered from respiratory ...

Babies born to mothers who contracted a COVID-19 infection while pregnant have “unusually high rates” of respiratory distress at birth or shortly after, a Nature Communications study found. While ...

Respiratory syncytial virus (RSV) mimics the symptoms of a really bad cold. It is especially dangerous for premature babies and children with existing lung or heart ailments and generally requires ...